4.4 Article

The human immunodeficiency virus type 1 Vpr protein upregulates PVR via activation of the AIR-mediated DNA damage response pathway

期刊

JOURNAL OF GENERAL VIROLOGY
卷 94, 期 -, 页码 2664-2669

出版社

MICROBIOLOGY SOC
DOI: 10.1099/vir.0.055541-0

关键词

-

资金

  1. Italian Ministry of Health
  2. Ricerca Corrente
  3. Italian 5 x 1000 contribution

向作者/读者索取更多资源

Viral infection may induce the cell-surface expression of PVR (CD155) that, upon recognition by its cognate activating DNAM-1 receptor present on cytotoxic lymphocytes, may promote antiviral immune responses. Here we show that expression of the human immunodeficiency virus type 1 (HIV-1) Vpr protein in Jurkat T cells increases cell-surface and total PVR levels. Analysis of mutated Vpr variants indicated that Vpr uses the same protein surfaces, and hence probably the same mechanisms, to upregulate PVR and arrest the cell cycle in the G(2) phase. Moreover, we found that PVR upregulation by Vpr relied on the ability of the protein to activate the ATR kinase that triggers the DNA damage response pathway and G(2) arrest. Finally, we showed that Vpr contributes to PVR up-modulation in HIV-infected CD4(+) T lymphocytes and inhibits the PVR downregulating activity of the viral Nef protein.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Immunology

Humoral and T-Cell Immune Response After 3 Doses of Messenger RNA Severe Acute Respiratory Syndrome Coronavirus 2 Vaccines in Fragile Patients: The Italian VAX4FRAIL Study

Paolo Corradini, Chiara Agrati, Giovanni Apolone, Alberto Mantovani, Diana Giannarelli, Vincenzo Marasco, Veronica Bordoni, Alessandra Sacchi, Giulia Matusali, Carlo Salvarani, Pier Luigi Zinzani, Renato Mantegazza, Fabrizio Tagliavini, Maria Teresa Lupo-Stanghellini, Fabio Ciceri, Silvia Damian, Antonio Uccelli, Daniela Fenoglio, Nicola Silvestris, Fausto Baldanti, Giulia Piaggio, Gennaro Ciliberto, Aldo Morrone, Franco Locatelli, Valentina Sinno, Maria Rescigno, Massimo Costantini

Summary: This study investigated the immune response to the SARS-CoV-2 vaccine in patients with tumors and immune disorders. The results showed that immunosuppressive treatment was a risk factor for a low humoral response, while the booster dose improved both humoral and T-cell responses.

CLINICAL INFECTIOUS DISEASES (2023)

Article Multidisciplinary Sciences

Immunogenicity to COVID-19 mRNA vaccine third dose in people living with HIV

Alessandra Vergori, Alessandro Cozzi Lepri, Stefania Cicalini, Giulia Matusali, Veronica Bordoni, Simone Lanini, Silvia Meschi, Roberta Iannazzo, Valentina Mazzotta, Francesca Colavita, Ilaria Mastrorosa, Eleonora Cimini, Davide Mariotti, Lydia De Pascale, Alessandra Marani, Paola Galli, AnnaRosa Garbuglia, Concetta Castilletti, Vincenzo Puro, Chiara Agrati, Enrico Girardi, Francesco Vaia, Andrea Antinori

Summary: HIV-infected individuals showed a strong humoral response after the third dose of a SARS-CoV-2 vaccine, while their cell-mediated immunity remained stable. This study highlights the usefulness of a third vaccine dose in people living with HIV who are on suppressive antiretroviral therapy.

NATURE COMMUNICATIONS (2022)

Article Immunology

Comparative analysis of the neutralizing activity against SARS-CoV-2 Wuhan-Hu-1 strain and variants of concern: Performance evaluation of a pseudovirus-based neutralization assay

Luciana D'Apice, Maria Trovato, Giulia Gramigna, Francesca Colavita, Massimo Francalancia, Giulia Matusali, Silvia Meschi, Daniele Lapa, Aurora Bettini, Klizia Mizzoni, Luigi Aurisicchio, Antonino Di Caro, Concetta Castilletti, Piergiuseppe De Berardinis

Summary: This study assessed the neutralizing activity of sera against variants of SARS-CoV-2 using a pseudovirus-based neutralization assay (PVNA) and found that the emergence of new variants can affect vaccine efficacy. Additionally, booster doses were found to enhance neutralizing antibody levels against the Omicron BA.1 variant.

FRONTIERS IN IMMUNOLOGY (2022)

Article Immunology

Safety and immune response kinetics of GRAd-COV2 vaccine: phase 1 clinical trial results

Chiara Agrati, Concetta Castilletti, Simone Battella, Eleonora Cimini, Giulia Matusali, Andrea Sommella, Alessandra Sacchi, Francesca Colavita, Alessandra M. Contino, Veronica Bordoni, Silvia Meschi, Giulia Gramigna, Federica Barra, Germana Grassi, Licia Bordi, Daniele Lapa, Stefania Notari, Rita Casetti, Aurora Bettini, Massimo Francalancia, Federica Ciufoli, Alessandra Vergori, Serena Vita, Michela Gentile, Angelo Raggioli, Maria M. Plazzi, Antonella Bacchieri, Emanuele Nicastri, Andrea Antinori, Stefano Milleri, Simone Lanini, Stefano Colloca, Enrico Girardi, Roberto Camerini, Giuseppe Ippolito, Francesco Vaia, Antonella Folgori, Stefania Capone

Summary: This study reports on the dynamics of humoral and T-cell response to the GRAd-COV2 vaccine, a gorilla adenoviral vector-based candidate for SARS-CoV-2. Spike-specific binding and neutralizing antibodies were induced and maintained for up to 3 months after a single intramuscular administration, while T-cell responses remained potent throughout the 6-month follow-up. No significant differences in immune response were observed between young and old volunteers. These findings suggest that GRAd-COV2 is a promising vaccine candidate for further clinical development and to combat the SARS-CoV-2 pandemic.

NPJ VACCINES (2022)

Article Immunology

Neutralizing antibodies to Omicron after the fourth SARS-CoV-2 mRNA vaccine dose in immunocompromised patients highlight the need of additional boosters

Maria Rescigno, Chiara Agrati, Carlo Salvarani, Diana Giannarelli, Massimo Costantini, Alberto Mantovani, Raffaella Massafra, Pier Luigi Zinzani, Aldo Morrone, Stefania Notari, Giulia Matusali, Giuseppe Lauria Pinter, Antonio Uccelli, Gennaro Ciliberto, Fausto Baldanti, Franco Locatelli, Nicola Silvestris, Valentina Sinno, Elena Turola, Maria Teresa Lupo-Stanghellini, Giovanni Apolone

Summary: This study compared the B-cell, T-cell, and neutralizing antibody response to WT and Omicron BA.2 SARS-CoV-2 virus in patients with hematological malignancies, solid tumors, and immune-rheumatological diseases after the fourth dose of mRNA COVID-19 vaccine. The T-cell response was similarly boosted by the fourth dose across different subgroups, while the antibody response was improved only in patients not receiving B-cell targeted therapies. However, a small percentage of patients did not have neutralizing antibodies to either virus variants, making them vulnerable to SARS-CoV-2 infection. The increment of neutralizing antibodies was similar towards Omicron BA.2 and WT virus after the third or fourth dose of vaccine. Additional booster doses are recommended for frail patients to enhance the development of a B-cell response against Omicron and/or to enhance the T-cell response in patients treated with anti-CD20.

FRONTIERS IN IMMUNOLOGY (2023)

Article Virology

Profiling the acute phase antibody response against mpox virus in patients infected during the 2022 outbreak

Francesca Colavita, Giulia Matusali, Valentina Mazzotta, Aurora Bettini, Daniele Lapa, Silvia Meschi, Massimo Francalancia, Carmela Pinnetti, Licia Bordi, Klizia Mizzoni, Sabrina Coen, Enrico Girardi, Francesco Vaia, Emanuele Nicastri, Andrea Antinori, Fabrizio Maggi

Summary: This study describes the short-term kinetics of the antibody response in MPXV-infected patients during the 2022 multicountry outbreak. The results show that IgG, IgM, and IgA antibodies were detected as early as 4 days after symptom onset, while neutralizing antibodies were detectable after 1 week. There were no significant differences in antibody levels regardless of smallpox vaccination status, HIV positivity, or disease severity. Lower levels of IgM and IgG were observed in patients treated with antivirals.

JOURNAL OF MEDICAL VIROLOGY (2023)

Article Medicine, General & Internal

Detection of SARS-CoV-2 Variants via Different Diagnostics Assays Based on Single-Nucleotide Polymorphism Analysis

Eliana Specchiarello, Giulia Matusali, Fabrizio Carletti, Cesare Ernesto Maria Gruber, Lavinia Fabeni, Claudia Minosse, Emanuela Giombini, Martina Rueca, Fabrizio Maggi, Alessandra Amendola, Anna Rosa Garbuglia

Summary: In this study, the performance of three methods for detecting SARS-CoV-2 variants was evaluated. Novaplex showed the highest ability to detect the Omicron subtype, while Allplex showed the highest ability to detect the Delta subtype. At the same time, Novaplex was able to resolve samples that could not be determined by TaqPath. The results of this study demonstrate the high efficiency of SNP-based methods for identifying viral variants.

DIAGNOSTICS (2023)

Article Biochemistry & Molecular Biology

SARS-CoV-2 Breakthrough Infections According to the Immune Response Elicited after mRNA Third Dose Vaccination in COVID-19-Naive Hospital Personnel

Annapaola Santoro, Andrea Capri, Daniele Petrone, Francesca Colavita, Silvia Meschi, Giulia Matusali, Klizia Mizzoni, Stefania Notari, Chiara Agrati, Delia Goletti, Patrizio Pezzotti, Vincenzo Puro

Summary: This study investigated the incidence of vaccine breakthrough infections in COVID-19-free individuals after receiving the mRNA third dose vaccine, based on B- and T-cell immune responses. The results showed that there were no protective thresholds for SARS-CoV-2 infection in terms of antibody levels or cellular immune response. Therefore, measuring vaccine-induced humoral immune response is not recommended as a marker for assessing protective immunity against SARS-CoV-2.

BIOMEDICINES (2023)

Letter Immunology

Asymptomatic Monkeypox virus Infection in Subjects Presenting for MVA-BN Vaccine

Giulia Matusali, Valentina Mazzotta, Pierluca Piselli, Aurora Bettini, Francesca Colavita, Sabrina Coen, Francesco Vaia, Enrico Girardi, Andrea Antinori, Fabrizio Maggi

CLINICAL INFECTIOUS DISEASES (2023)

Article Immunology

Older Age, a High Titre of Neutralising Antibodies and Therapy with Conventional DMARDs Are Associated with Protection from Breakthrough Infection in Rheumatoid Arthritis Patients after the Booster Dose of Anti-SARS-CoV-2 Vaccine

Andrea Picchianti-Diamanti, Assunta Navarra, Alessandra Aiello, Bruno Lagana, Gilda Cuzzi, Andrea Salmi, Valentina Vanini, Fabrizio Maggi, Silvia Meschi, Giulia Matusali, Stefania Notari, Chiara Agrati, Simonetta Salemi, Roberta Di Rosa, Damiano Passarini, Valeria Di Gioia, Giorgio Sesti, Fabrizio Conti, Francesca Romana Spinelli, Angela Corpolongo, Maria Sole Chimenti, Mario Ferraioli, Gian Domenico Sebastiani, Maurizio Benucci, Francesca Li Gobbi, Anna Paola Santoro, Andrea Capri, Vincenzo Puro, Emanuele Nicastri, Delia Goletti

Summary: Breakthrough infections (BIs) in rheumatoid arthritis (RA) patients after a COVID-19 vaccination booster dose were analyzed. Older age, receiving conventional synthetic disease modifying antirheumatic drugs (csDMARDs), and higher neutralising antibody titres were identified as protective factors, while anti-IL6R treatment and anti-CD20 therapy increased the risk. The incidence of hospitalization for BIs was significantly higher in RA patients compared to healthcare workers.

VACCINES (2023)

Article Immunology

Torquetenovirus Loads in Peripheral Blood Predict Both the Humoral and Cell-Mediated Responses to SARS-CoV-2 Elicited by the mRNA Vaccine in Liver Transplant Recipients

Claudia Minosse, Giulia Matusali, Silvia Meschi, Germana Grassi, Massimo Francalancia, Gianpiero D'Offizi, Pietro Giorgio Spezia, Anna Rosa Garbuglia, Marzia Montalbano, Daniele Focosi, Enrico Girardi, Francesco Vaia, Giuseppe Maria Ettorre, Fabrizio Maggi

Summary: TTV viremia levels before vaccination in liver transplant recipients can predict their serum antibody response and cell-mediated immunity, but are not associated with serum neutralizing antibody titers.

VACCINES (2023)

Article Immunology

Evaluation of Cross-Immunity to the Mpox Virus Due to Historic Smallpox Vaccination

Giulia Matusali, Elisa Petruccioli, Eleonora Cimini, Francesca Colavita, Aurora Bettini, Eleonora Tartaglia, Settimia Sbarra, Silvia Meschi, Daniele Lapa, Massimo Francalancia, Licia Bordi, Valentina Mazzotta, Sabrina Coen, Klizia Mizzoni, Alessia Beccacece, Emanuele Nicastri, Luca Pierelli, Andrea Antinori, Enrico Girardi, Francesco Vaia, Alessandro Sette, Alba Grifoni, Delia Goletti, Vincenzo Puro, Fabrizio Maggi

Summary: This study found that a high proportion of individuals who received the smallpox vaccine 40 to 60 years ago have humoral cross-immunity to MPXV, while a smaller group of vaccinated individuals showed a T-cell-specific response against MPXV.

VACCINES (2023)

Article Infectious Diseases

Rapid and qualitative identification of SARS-CoV-2 mutations associated with variants of concern using a multiplex RT-PCR assay coupled with melting analysis

Giuseppe Sberna, Lavinia Fabeni, Giulia Berno, Fabrizio Carletti, Eliana Specchiarello, Francesca Colavita, Silvia Meschi, Giulia Matusali, Anna Rosa Garbuglia, Licia Bordi, Eleonora Lalle

Summary: The study evaluated the performance of the Simplexa (R) SARS-CoV-2 Variant Direct assay in rapidly detecting SARS-CoV-2 variants, with majority of the samples showing agreement with standard sequencing results. The assay demonstrated 100% sensitivity and specificity for detecting Alpha, Beta, Gamma, Delta, and Omicron variants.

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2022)

Article Cell Biology

SARS-CoV-2 Infection of Airway Epithelium Triggers Pulmonary Endothelial Cell Activation and Senescence Associated with Type I IFN Production

Veronica Bordoni, Davide Mariotti, Giulia Matusali, Francesca Colavita, Eleonora Cimini, Giuseppe Ippolito, Chiara Agrati

Summary: Airway epithelial cells infected with SARS-CoV-2 trigger activation and senescence processes in pulmonary endothelial cells, involving the production of type I IFN-beta. This suggests the existence of antiviral and damage mechanisms in the endothelium.
Meeting Abstract Gastroenterology & Hepatology

Third dose of SARS-COV2 mRNA-vaccine in liver transplant recipients: can it bridge the response gap?

Marzia Montalbano, Raffaella Lionetti, Ubaldo Visco Comandini, Silvia Meschi, Chiara Agrati, Federica Conte, Vincenzo Puro, Paola Piccolo, Giulia Matusali, Germana Grassi, Tiziana Mereu, Federica Angelone, Enrico Girardi, Giuseppe Maria Ettorre, Giampiero D'Offizi

JOURNAL OF HEPATOLOGY (2022)

暂无数据